As per the report, the size of the Hemophilia Management Market in the Asia Pacific was worth USD 1038.16 million in 2021 and estimated to be growing at a CAGR of 1.78%, worth USD 1133.90 million by 2026.
Hemophilia is characterized into three levels depending upon its severity as severe, moderate and mild. Around 80% of the patients suffering from hemophilia are considered to be severe. The worldwide incidence of hemophilia is estimated at more than 400,000 people.
Asia-Pacific Hemophilia Management market is driven by factors such as the growing prevalence of the disease and the increasing usage of recombinant products. Advancements in technology and rising investments into Research and developments are also fuelling market growth.
However, lack of awareness about the disease and limited access to the medication are the key factors hindering the market growth. Advancements in gene therapy which help in the treatment of hemophilia also provide immense growth opportunities.
This research report on the APAC Hemophilia Management Market is segmented and sub-segmented into the following categories:
By Type:
By Drug:
By Country:
Regionally, the Asia-Pacific region is estimated to be the fastest-growing region owing to its high population base and increasing healthcare expenditure. Within Asia-Pacific, Japan is a major market for hemophilia management due to high government support and widespread awareness about the treatment options for hemophilia. India is estimated to grow at the highest CAGR due to increasing incidence of hemophilia.
Noteworthy companies in the APAC Hemophilia Management Market profiled in this report are Biogen, Baxter International Inc., Pfizer Inc., Bayer Pharma AG, Novo Nordisk A/S, Grifols International SA, CSL Behring, Octapharma and Swedish Orphan Biovitrum AB
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5.1 BY Type
5.1.1 Hemophilia A
5.1.2 Hemophilia B
5.2 By Drug
5.2.1 Octocogalfa
5.2.2 Nonacogalfa
5.2.3 Desmopressin
5.2.4 Other drugs
6.3 Asia-Pacific
6.1 Introduction
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.1 Biogen
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Pfizer Inc.
8.3 Baxter International Inc.
8.4 Bayer Pharma AG
8.5 Novo Nordisk A/S
8.6 Grifols International SA
8.7 CSL Behring
8.8 Octapharma
8.9 Swedish Orphan Biovitrum AB
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
